Charles G. Helmick III, MD, Retires After 42 Years with the CDC On Dec. 31, 2021, after 42 years of service, Charles (Chad) G. Helmick III, MD (Capt., USPHS, Ret.), officially retired from the Centers for Disease Control and Prevention. He joined the CDC in 1979, when Jimmy Carter was president, and served through eight…
ORLANDO—Despite the COVID-19 pandemic, the past two years have been exciting for rheumatology providers and patients. We’ve seen the U.S. Food & Drug Administration (FDA) approve new therapies and expand indications for established drugs. At the 2022 ACR Education Exchange, Jeffrey Curtis, MD, MS, MPH, Marguerite Jones Harbert-Gene Ball Endowed professor of medicine, Division of…
It is better to be feared than loved. The associate dean of student affairs at my medical school embraced this motto. Although the dean of the medical school was titularly in charge, it was the associate dean who kept the school running. And we all feared her, just a little bit. Without ever raising her…
The treatment and management of rheumatoid arthritis (RA) is ever evolving. Here Clifton O. Bingham, MD, discusses the application of RA guidelines, the most recent drug safety information and more.
Ana-Maria Orbai, MD, MHS, addressed the latest research into psoriatic arthritis (PsA), including a comprehensive overview of the latest FDA-approved treatments and their implications for clinical practice.
Meghan Berkenstock, MD, summarized key clinical pearls related to uveitis and rheumatic diseases during a session of the 18th Annual Advances in the Diagnosis & Treatment of the Rheumatic Diseases symposium.
A prospective observational study by Syversen et al. found that patients with immune-mediated inflammatory diseases (IMID) had an attenuated serologic response to the standard two-dose vaccine regimen but a third dose was safe and effective.
Glucocorticoids remain a prominent part of care for many patients with SLE but can have toxic side effects; this EULAR 2022 session discussed one institution’s approach to lower the dosage.
Research has demonstrated that deucravacitinib is significantly more efficacious than placebo for achieving minimal disease activity in patients with active PsA after 16 weeks of treatment.
In a study from Ramanan et al., baricitinib proved safe and effective for reducing the time to flare and frequency of flare in patients aged 2–18 years with juvenile idiopathic arthritis.